This article was collected and archived by Digital Sovereignty Watch from an institutional or public source relevant to digital sovereignty, technology policy, cybersecurity, cloud services, artificial intelligence or European regulation.
Privacy
EDPB and EDPS support harmonisation of clinical trials under European Biotech Act, but call for specific safeguards for sensitive health data
Brussels, 12 March 2026 – The European Data Protection Board (EDPB) and the European Data Protection Supervisor (EDPS) have adopted a Joint Opinion on the European Commission’s Proposal for a European Biotech Act. The Proposal aims to strengthen Europe’s biotechnology and biomanufacturing sectors, particularly in the area of health, by streamlining the regulatory framework and updating the rules for clinical trials. The EDPB and the EDPS support the Proposal’s objective of fostering the EU’s competitiveness and addressing existing fragmentation in the application of the Clinical Trials Regulation (CTR). In particular, they welcome the aim to establish a single legal basis for the processing of personal data by sponsors and investigators, which will significantly improve legal clarity across Europe.